Compare RXT & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXT | RANI |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 126.8M |
| IPO Year | 2020 | 2021 |
| Metric | RXT | RANI |
|---|---|---|
| Price | $1.23 | $0.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $1.71 | ★ $7.80 |
| AVG Volume (30 Days) | ★ 7.4M | 1.5M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.13 | 57.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,685,700,000.00 | $1,633,000.00 |
| Revenue This Year | N/A | $321.62 |
| Revenue Next Year | $1.35 | $66.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $0.39 | $0.39 |
| 52 Week High | $2.74 | $3.87 |
| Indicator | RXT | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 49.76 |
| Support Level | $1.16 | $0.45 |
| Resistance Level | $1.32 | $1.22 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 68.27 | 55.20 |
Rackspace Technology Inc is an end-to-end, hybrid, multi-cloud technology services company. It designs, builds, and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services, Data, Colocation, Cloud, Managed Hosting, Professional Services, and Security and Compliance. It has two reportable segments: Private Cloud and Public Cloud. Maximum revenue is generated from the Public Cloud segment, which offers cloud solutions through managed services, elastic engineering, and professional services offerings for customer environments hosted on the AWS, Microsoft Azure, and Google Cloud public cloud platforms. Geographically, the company derives its key revenue from the U.S.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.